These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36978322)

  • 1. In Vitro Activity of Ceftolozane-Tazobactam against
    Perovic O; Singh-Moodley A; Lowe M
    Antibiotics (Basel); 2023 Feb; 12(3):. PubMed ID: 36978322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 3. Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Hernández-García M; García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Costa E; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Pássaro L; Paixão L; Romano J; Cantón R;
    Int J Antimicrob Agents; 2021 Feb; 57(2):106259. PubMed ID: 33310115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of
    Alfouzan W; Dhar R; Mohsin J; Khamis F; Mokaddas E; Abdullah A; Mustafa AS; Otero A; Wanis P; Matar SH; Khalil S; Alekseeva I; Young K
    JAC Antimicrob Resist; 2022 Apr; 4(2):dlac035. PubMed ID: 35465239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016.
    Kuo SC; Liu CE; Lu PL; Chen YS; Lu MC; Ko WC; Hsueh PR; Chuang YC; Wang FD;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105883. PubMed ID: 31923574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of ceftolozane/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon.
    Araj GF; Berjawi DM; Musharrafieh U; El Beayni NK
    J Infect Dev Ctries; 2020 Jun; 14(6):559-564. PubMed ID: 32683345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
    [No Abstract]   [Full Text] [Related]  

  • 8. Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017).
    Beirão EM; Rodrigues SDS; Andrade TK; Serra FB; Paula MDN; Polis TJB; Gales AC
    Braz J Infect Dis; 2020; 24(4):310-321. PubMed ID: 32663440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
    Sutherland CA; Nicolau DP
    Clin Ther; 2015 Jul; 37(7):1564-71. PubMed ID: 26088525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of
    Belkhair J; Nachat S; Rouhi S; Ouassif H; Abbassi S; Soraa N
    New Microbes New Infect; 2021 May; 41():100872. PubMed ID: 33912351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole Genome Sequence Analysis of Multidrug Resistant
    Moghnia OH; Al-Sweih NA
    Microorganisms; 2022 Feb; 10(3):. PubMed ID: 35336083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended Spectrum β-Lactamase-Producing
    Chenouf NS; Carvalho I; Messaï CR; Ruiz-Ripa L; Mama OM; Titouche Y; Zitouni A; Hakem A; Torres C
    Microb Drug Resist; 2021 Feb; 27(2):268-276. PubMed ID: 32609048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6305-10. PubMed ID: 24100499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
    Shortridge D; Duncan LR; Pfaller MA; Flamm RK
    Int J Antimicrob Agents; 2019 May; 53(5):637-643. PubMed ID: 30716448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals.
    Bahabri NM; Al-Alawi MM; Qutub MO; Tashkandi WA; AlTurki R; Janah SS; Ali HE; Almutairi AF; Khalil S
    J Infect Public Health; 2022 Apr; 15(4):486-490. PubMed ID: 35221238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.